相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PCB153 reduces apoptosis in primary cultures of murine pituitary cells through the activation of NF-κB mediated by PI3K/Akt
Claudio Urbani et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2021)
Cushing's syndrome: Treatment and new therapeutic approaches
Amandine Ferriere et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
USP8 Mutations and Cell Cycle Regulation in Corticotroph Adenomas
Clarissa Silva Martins et al.
HORMONE AND METABOLIC RESEARCH (2020)
Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors
Mari C. Vazquez-Borrego et al.
NEUROENDOCRINOLOGY (2020)
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
Rosario Pivonello et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials
Rosario Pivonello et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Germline and mosaic mutations causing pituitary tumours: genetic and molecular aspects
Sara Pepe et al.
JOURNAL OF ENDOCRINOLOGY (2019)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
AFAP1-AS1 Promotes Proliferation of Pituitary Adenoma Cells through miR-103a-3p to Activate PI3K/AKT Signaling Pathway
HengXin Tang et al.
WORLD NEUROSURGERY (2019)
COL6A6 interacted with P4HA3 to suppress the growth and metastasis of pituitary adenoma via blocking PI3K-Akt pathway
Ruiqing Long et al.
AGING-US (2019)
Targeting mTOR and Metabolism in Cancer: Lessons and Innovations
Cedric Magaway et al.
CELLS (2019)
HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis
Monica Fedele et al.
CELL CYCLE (2018)
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting
Claudia Pivonello et al.
ENDOCRINE (2018)
Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside
Anat Ben-Shlomo et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2017)
Effect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT
Zhiming Zheng et al.
MEDICAL SCIENCE MONITOR (2017)
Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Adrenocorticotropic Hormone Production and Tumorous Corticotroph Cell Growth in AtT20 Cells
Fang-Fang Jian et al.
CHINESE MEDICAL JOURNAL (2016)
P27/CDKN1B Translational Regulators in Pituitary Tumorigenesis
C. S. Martins et al.
HORMONE AND METABOLIC RESEARCH (2016)
Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors
Marie Chanal et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Recurrent gain-of-function USP8 mutations in Cushing's disease
Zeng-Yi Ma et al.
CELL RESEARCH (2015)
The Treatment of Cushing's Disease
Rosario Pivonello et al.
ENDOCRINE REVIEWS (2015)
Decoding the genetic basis of Cushing's disease: USP8 in the spotlight
Marily Theodoropoulou et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
Lynnette K. Nieman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
TMEFF2 is an endogenous inhibitor of the CRH signal transduction pathway
Marta Labeur et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2015)
Mutations in the deubiquitinase gene USP8 cause Cushing's disease
Martin Reincke et al.
NATURE GENETICS (2015)
The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas
Eric Monsalves et al.
ENDOCRINE-RELATED CANCER (2014)
Inhibition of Phosphatidylinositol 3-Kinase/AKT Signaling by NVP-BKM120 Promotes ABT-737-Induced Toxicity in a Caspase-Dependent Manner through Mitochondrial Dysfunction and DNA Damage Response in Established and Primary Cultured Glioblastoma Cells
Esther P. Jane et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
Pascal Furet et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Inhibition of PI3K/AKT/mTOR Pathway Enhances Temozolomide-Induced Cytotoxicity in Pituitary Adenoma Cell Lines in Vitro and Xenografted Pituitary Adenoma in Female Nude Mice
Congxin Dai et al.
ENDOCRINOLOGY (2013)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
Saskia M. Brachmann et al.
MOLECULAR CANCER THERAPEUTICS (2012)
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
Hidenori Fukuoka et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Matthew T. Burger et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Platelet-derived Growth Factor (PDGF) and PDGF Receptor Expression and Function in Folliculostellate Pituitary Cells
M. Kowarik et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2010)
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors
Yong Lin et al.
ENDOCRINE-RELATED CANCER (2009)
Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors
Changxue Lu et al.
ENDOCRINOLOGY (2008)
Regulation of the RAP1/RAF-1/extracellularly regulated kinase-1/2 cascade and prolactin release by the phosphoinositide 3-kinase/AKT pathway in pituitary cells
David Romano et al.
ENDOCRINOLOGY (2006)
Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression
M Theodoropoulou et al.
CANCER RESEARCH (2006)
Enhanced protein kinase B/Akt signalling in pituitary tumours
M Musat et al.
ENDOCRINE-RELATED CANCER (2005)
The luteinizing hormone-releasing hormone inhibits the anti-apoptotic activity of insulin-like growth factor-1 in pituitary αT3 cells by protein kinase Cα-mediated negative regulation of Akt
A Rose et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
